Warner Chilcott Announces FDA Approval of New Oral Contraceptive

Warner Chilcott Announces FDA Approval of New Oral Contraceptive

DUBLIN, Ireland, July 25, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc
(Nasdaq:WCRX) today announced that the United States Food and Drug
Administration (FDA) has approved LO MINASTRIN™ FE (norethindrone acetate and
ethinyl estradiol chewable tablets, ethinyl estradiol tablets and ferrous
fumarate tablets) for the prevention of pregnancy. The Company is currently
developing the commercial launch plans for LO MINASTRIN FE.

"We are pleased to announce the approval of LO MINASTRIN FE, which marks the
fifth FDA-approved product for the Company since the beginning of 2013," noted
Roger Boissonneault, President and CEO of Warner Chilcott.

About LO MINASTRIN FE

LO MINASTRIN FE is indicated for use by females of reproductive age to prevent
pregnancy.

Important Safety Information

Cigarette smoking increases the risk of serious cardiovascular events from
combination oral contraceptive (COC) use. This risk increases with age,
particularly in women over 35 years of age, and with the number of cigarettes
smoked. For this reason, COCs should not be used by women who are over 35
years of age and smoke.

For additional information, including information on dosage and
administration, contraindications, warnings and precautions, adverse
reactions, and other important safety and other prescribing information, see
http://www.wcrx.com/pdfs/pi/lo_minastrin.pdf.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently
focused on the women's healthcare, gastroenterology, urology and dermatology
segments of the branded pharmaceuticals market, primarily in North America. We
are a fully integrated company with internal resources dedicated to the
development, manufacture and promotion of our products. WCRX-G

Forward Looking Statements

This press release contains forward-looking statements, including statements
concerning the proposed transaction with Actavis, our industry, our
operations, our anticipated financial performance and financial condition and
our business plans, growth strategy and product development efforts. These
statements constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. The words "may," "might," "will," "should," "estimate,"
"project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and
other similar expressions are intended to identify forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates. These forward-looking
statements are based on estimates and assumptions by our management that,
although we believe to be reasonable, are inherently uncertain and subject to
a number of risks and uncertainties. The following represent some, but not
necessarily all, of the factors that could cause actual results to differ from
historical results or those anticipated or predicted by our forward-looking
statements: the timing to consummate the proposed transaction with Actavis;
the risk that a condition to closing of the proposed transaction with Actavis
may not be satisfied; the risk that a regulatory approval that may be required
for the proposed transaction with Actavis is delayed, is not obtained or is
obtained subject to conditions that are not anticipated; New Actavis' ability
to achieve the synergies and value creation contemplated by the proposed
acquisition; New Actavis' ability to promptly and effectively integrate
Actavis' and our businesses; the diversion of management time on
transaction-related issues; our substantial indebtedness, including increases
in the LIBOR rates on our variable-rate indebtedness above the applicable
floor amounts; competitive factors and market conditions in the industry in
which we operate, including the approval and introduction of generic or
branded products that compete with our products; our ability to protect our
intellectual property; a delay in qualifying any of our manufacturing
facilities that produce our products, production or regulatory problems with
either our own manufacturing facilities or those of third party manufacturers,
packagers or API suppliers upon whom we may rely for some of our products or
other disruptions within our supply chain; pricing pressures from
reimbursement policies of private managed care organizations and other third
party payors, government sponsored health systems and regulatory reforms, and
the continued consolidation of the distribution network through which we sell
our products; changes in tax laws or interpretations that could increase our
consolidated tax liabilities; government regulation, including U.S. and
foreign health care reform, affecting the development, manufacture, marketing
and sale of pharmaceutical products, including our ability and the ability of
companies with whom we do business to obtain necessary regulatory approvals;
adverse outcomes in our outstanding litigation, regulatory investigations or
arbitration matters or an increase in the number of such matters to which we
are subject; the loss of key senior management or scientific staff; our
ability to manage the growth of our business by successfully identifying,
developing, acquiring or licensing new products at favorable prices and
marketing such new products; our ability to obtain regulatory approval and
customer acceptance of new products, and continued customer acceptance of our
existing products; and the other risks identified in our periodic filings
including our Annual Report on Form 10-K for the year ended December 31, 2012,
and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.
In addition, in light of these risks and uncertainties, the matters referred
to in our forward-looking statements may not occur. We undertake no obligation
to publicly update or revise any forward-looking statement as a result of new
information, future events or otherwise, except as may be required by law.

CONTACT: Rochelle Fuhrmann
         Senior Vice President, Finance
         973-442-3281
         rfuhrmann@wcrx.com
        
         Kevin Crissey
         Director, Investor Relations
         973-907-7084
         kevin.crissey@wcrx.com

Warner Chilcott Logo
 
Press spacebar to pause and continue. Press esc to stop.